请输入您要查询的百科知识：

　

词条 Chromatin remodeling
释义

  1. Overview

  2. Classification

     Covalent histone-modifying complexes  Known modifications  Histone code hypothesis  ATP-dependent chromatin remodeling  Known chromatin remodeling complexes  Specific functions 

  3. Significance

     In normal biological processes  Response to DNA damage  Cancer  Cancer genomics  Therapeutic intervention  Other disease syndromes  Aging 

  4. See also

  5. Further reading

  6. References

  7. External links

Chromatin remodeling is the dynamic modification of chromatin architecture to allow access of condensed genomic DNA to the regulatory transcription machinery proteins, and thereby control gene expression. Such remodeling is principally carried out by 1) covalent histone modifications by specific enzymes, e.g., histone acetyltransferases (HATs), deacetylases, methyltransferases, and kinases, and 2) ATP-dependent chromatin remodeling complexes which either move, eject or restructure nucleosomes.[1] Besides actively regulating gene expression, dynamic remodeling of chromatin imparts an epigenetic regulatory role in several key biological processes, egg cells DNA replication and repair; apoptosis; chromosome segregation as well as development and pluripotency. Aberrations in chromatin remodeling proteins are found to be associated with human diseases, including cancer. Targeting chromatin remodeling pathways is currently evolving as a major therapeutic strategy in the treatment of several cancers.

Overview

The transcriptional regulation of the genome is controlled primarily at the preinitiation stage by binding of the core transcriptional machinery proteins (namely, RNA polymerase, transcription factors, and activators and repressors) to the core promoter sequence on the coding region of the DNA. However, DNA is tightly packaged in the nucleus with the help of packaging proteins, chiefly histone proteins to form repeating units of nucleosomes which further bundle together to form condensed chromatin structure. Such condensed structure occludes many DNA regulatory regions, not allowing them to interact with transcriptional machinery proteins and regulate gene expression. To overcome this issue and allow dynamic access to condensed DNA, a process known as chromatin remodeling alters nucleosome architecture to expose or hide regions of DNA for transcriptional regulation.

By definition, chromatin remodeling is the enzyme-assisted process to facilitate access of nucleosomal DNA by remodeling the structure, composition and positioning of nucleosomes.

Classification

Access to nucleosomal DNA is governed by two major classes of protein complexes:

  1. Covalent histone-modifying complexes.
  2. ATP-dependent chromatin remodeling complexes.

Covalent histone-modifying complexes

Specific protein complexes, known as histone-modifying complexes catalyze addition or removal of various chemical elements on histones. These enzymatic modifications include acetylation, methylation, phosphorylation, and ubiquitination and primarily occur at N-terminal histone tails. Such modifications affect the binding affinity between histones and DNA, and thus loosening or tightening the condensed DNA wrapped around histones, e.g., Methylation of specific lysine residues in H3 and H4 causes further condensation of DNA around histones, and thereby preventing binding of transcription factors to the DNA leading to gene repression. On contrary, histone acetylation relaxes chromatin condensation and exposes DNA for TF binding, leading to increase gene expression.[2]

Known modifications

Well characterized modifications to histones include:[3]

  • Methylation

Both lysine and arginine residues are known to be methylated. Methylated lysines are the best understood marks of the histone code, as specific methylated lysine match well with gene expression states. Methylation of lysines H3K4 and H3K36 is correlated with transcriptional activation while demethylation of H3K4 is correlated with silencing of the genomic region. Methylation of lysines H3K9 and H3K27 is correlated with transcriptional repression.[4] Particularly, H3K9me3 is highly correlated with constitutive heterochromatin.[5]

  • Acetylation - by HAT (histone acetyl transferase); deacetylation - by HDAC (histone deacetylase)

Acetylation tends to define the ‘openness’ of chromatin as acetylated histones cannot pack as well together as deacetylated histones.

  • Phosphorylation
  • Ubiquitination

However, there are many more histone modifications, and sensitive mass spectrometry approaches have recently greatly expanded the catalog.[6]

Histone code hypothesis

The histone code is a hypothesis that the transcription of genetic information encoded in DNA is in part regulated by chemical modifications to histone proteins, primarily on their unstructured ends. Together with similar modifications such as DNA methylation it is part of the epigenetic code.

Cumulative evidence suggests that such code is written by specific enzymes which can (for example) methylate or acetylate DNA ('writers'), removed by other enzymes having demethylase or deacetylase activity ('erasers'), and finally readily identified by proteins (‘readers’) that are recruited to such histone modifications and bind via specific domains, e.g., bromodomain, chromodomain. These triple action of ‘writing’, ‘reading’ and ‘erasing’ establish the favorable local environment for transcriptional regulation, DNA-damage repair, etc.[7]

The critical concept of the histone code hypothesis is that the histone modifications serve to recruit other proteins by specific recognition of the modified histone via protein domains specialized for such purposes, rather than through simply stabilizing or destabilizing the interaction between histone and the underlying DNA. These recruited proteins then act to alter chromatin structure actively or to promote transcription.

A very basic summary of the histone code for gene expression status is given below (histone nomenclature is described here):

Type of
modification		Histone
H3K4 H3K9 H3K14 H3K27 H3K79 H4K20 H2BK5
mono-methylation activation[8] activation[9] activation[9] activation[9][10] activation[9] activation[9]
di-methylationrepression[4] repression[4] activation[10]
tri-methylation activation[11] repression[9] repression[9] activation,[10]
repression[9]		 repression[4]
acetylation activation[11] activation[11]

ATP-dependent chromatin remodeling

ATP-dependent chromatin-remodeling complexes regulate gene expression by either moving, ejecting or restructuring nucleosomes. These protein complexes have a common ATPase domain and energy from the hydrolysis of ATP allows these remodeling complexes to reposition (slide, twist or loop) nucleosomes along the DNA, expel histones away from DNA or facilitate exchange of histone variants, and thus creating nucleosome-free regions of DNA for gene activation.[12] Also, several remodelers have DNA-translocation activity to carry out specific remodeling tasks.[13]

Known chromatin remodeling complexes

There are at least five families of chromatin remodelers in eukaryotes: SWI/SNF, ISWI, NuRD/Mi-2/CHD, INO80 and SWR1 with first two remodelers being very well studied so far, especially in the yeast model. Although all of remodelers share common ATPase domain, their functions are specific based on several biological processes (DNA repair, apoptosis, etc.). This is due to the fact that each remodeler complex has unique protein domains (Helicase, bromodomain, etc.) in their catalytic ATPase region and also has different recruited subunits.

Specific functions

  • Several in-vitro experiments suggest that ISWI remodelers organize nucleosome into proper bundle form and create equal spacing between nucleosomes, whereas SWI/SNF remodelers disorder nucleosomes.
  • The ISWI-family remodelers have been shown to play central roles in chromatin assembly after DNA replication and maintenance of higher-order chromatin structures.
  • INO80 and SWI/SNF-family remodelers participate in DNA double-strand break (DSB) repair and nucleotide-excision repair (NER) and thereby plays crucial role in TP53 mediated DNA-damage response.
  • NuRD/Mi-2/CHD remodeling complexes primarily mediate transcriptional repression in the nucleus and are required for the maintenance of pluripotency of embryonic stem cells.[12]

Significance

In normal biological processes

Chromatin remodeling plays a central role in the regulation of gene expression by providing the transcription machinery with dynamic access to an otherwise tightly packaged genome. Further, nucleosome movement by chromatin remodelers is essential to several important biological processes, including chromosome assembly and segregation, DNA replication and repair, embryonic development and pluripotency, and cell-cycle progression. Deregulation of chromatin remodeling causes loss of transcriptional regulation at these critical check-points required for proper cellular functions, and thus causes various disease syndromes, including cancer.

Response to DNA damage

Chromatin relaxation is one of the earliest cellular responses to DNA damage.[14] The relaxation appears to be initiated by PARP1, whose accumulation at DNA damage is half complete by 1.6 seconds after DNA damage occurs.[15] This is quickly followed by accumulation of chromatin remodeler Alc1, which has an ADP-ribose–binding domain, allowing it to be quickly attracted to the product of PARP1. The maximum recruitment of Alc1 occurs within 10 seconds of DNA damage.[14] About half of the maximum chromatin relaxation, presumably due to action of Alc1, occurs by 10 seconds.[14] PARP1 action at the site of a double-strand break allows recruitment of the two DNA repair enzymes MRE11 and NBS1. Half maximum recruitment of these two DNA repair enzymes takes 13 seconds for MRE11 and 28 seconds for NBS1.[15]

Another process of chromatin relaxation, after formation of a DNA double-strand break, employs γH2AX, the phosphorylated form of the H2AX protein. The histone variant H2AX constitutes about 10% of the H2A histones in human chromatin.[16] γH2AX (phosphorylated on serine 139 of H2AX) was detected at 20 seconds after irradiation of cells (with DNA double-strand break formation), and half maximum accumulation of γH2AX occurred in one minute.[16] The extent of chromatin with phosphorylated γH2AX is about two million base pairs at the site of a DNA double-strand break.[16]

γH2AX does not, by itself, cause chromatin decondensation, but within seconds of irradiation the protein “Mediator of the DNA damage checkpoint 1” (MDC1) specifically attaches to γH2AX.[17][18] This is accompanied by simultaneous accumulation of RNF8 protein and the DNA repair protein NBS1 which bind to MDC1 as MDC1 attaches to γH2AX.[19] RNF8 mediates extensive chromatin decondensation, through its subsequent interaction with CHD4 protein,[20] a component of the nucleosome remodeling and deacetylase complex NuRD. CHD4 accumulation at the site of the double-strand break is rapid, with half-maximum accumulation occurring by 40 seconds after irradiation.[21]

The fast initial chromatin relaxation upon DNA damage (with rapid initiation of DNA repair) is followed by a slow recondensation, with chromatin recovering a compaction state close to its predamage level in ∼ 20 min.[14]

Cancer

Chromatin remodeling provides fine-tuning at crucial cell growth and division steps, like cell-cycle progression, DNA repair and chromosome segregation, and therefore exerts tumor-suppressor function. Mutations in such chromatin remodelers and deregulated covalent histone modifications potentially favor self-sufficiency in cell growth and escape from growth-regulatory cell signals - two important hallmarks of cancer.[22]

  • Inactivating mutations in SMARCB1, formerly known as hSNF5/INI1 and a component of the human SWI/SNF remodeling complex have been found in large number of rhabdoid tumors, commonly affecting pediatric population.[23] Similar mutations are also present in other childhood cancers, such as choroid plexus carcinoma, medulloblastoma and in some acute leukemias. Further, mouse knock-out studies strongly support SMARCB1 as a tumor suppressor protein. Since the original observation of SMARCB1 mutations in rhabdoid tumors, several more subunits of the human SWI/SNF chromatin remodeling complex have been found mutated in a wide range of neoplasms.[24]
  • The SWI/SNF ATPase BRG1 (or SMARCA4) is the most frequently mutated chromatin remodeling ATPase in cancer.[25] Mutations in this gene were first recognized in human cancer cell lines derived from adrenal gland[26] and lung.[27] In cancer, mutations in BRG1 show an unusually high preference for missense mutations that target the ATPase domain.[28][25] Mutations are enriched at highly conserved ATPase sequences,[29] which lie on important functional surfaces such as the ATP pocket or DNA-binding surface.[28] These mutations act in a genetically dominant manner to alter chromatin regulatory function at enhancers[28] and promoters.[29]
  • PML-RAR fusion protein in acute myeloid leukemia recruits histone deacetylases. This leads to repression of gene responsible for myelocytes to differentiate, leading to leukemia.
  • Tumor suppressor Rb protein functions by the recruitment of the human homologs of the SWI/SNF enzymes BRG1, histone deacetylase and DNA methyltransferase. Mutations in BRG1 are reported in several cancers causing loss of tumor suppressor action of Rb.[30]
  • Recent reports indicate DNA hypermethylation in the promoter region of major tumor suppressor genes in several cancers. Although few mutations are reported in histone methyltransferases yet, correlation of DNA hypermethylation and histone H3 lysine-9 methylation has been reported in several cancers, mainly in colorectal and breast cancers.
  • Mutations in Histone Acetyl Transferases (HAT) p300 (missense and truncating type) are most commonly reported in colorectal, pancreatic, breast and gastric carcinomas. Loss of heterozygosity in coding region of p300 (chromosome 22q13) is present in large number of glioblastomas.
  • Further, HATs have diverse role as transcription factors beside having histone acetylase activity, e.g., HAT subunit, hADA3 may act as an adaptor protein linking transcription factors with other HAT complexes. In the absence of hADA3, TP53 transcriptional activity is significantly reduced, suggesting role of hADA3 in activating TP53 function in response to DNA-damage.
  • Similarly, TRRAP, the human homolog to yeast Tra1, has been shown to directly interact with c-Myc and E2F1 - known oncoproteins.

Cancer genomics

Rapid advance in cancer genomics and high-throughput ChIP-chip, ChIP-Seq and Bisulfite sequencing methods are providing more insight into role of chromatin remodeling in transcriptional regulation and role in cancer.

Therapeutic intervention

Epigenetic instability caused by deregulation in chromatin remodeling is studied in several cancers, including breast cancer, colorectal cancer, pancreatic cancer. Such instability largely cause widespread silencing of genes with primary impact on tumor-suppressor genes. Hence, strategies are now being tried to overcome epigenetic silencing with synergistic combination of HDAC inhibitors or HDI and DNA-demethylating agents.

HDIs are primarily used as adjunct therapy in several cancer types.[31][32] HDAC inhibitors can induce p21 (WAF1) expression, a regulator of p53's tumor suppressoractivity. HDACs are involved in the pathway by which the retinoblastoma protein (pRb) suppresses cell proliferation.[33] Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor alpha (ERα). Recent data indicate that chromatin inactivation mediated by HDAC and DNA methylation is a critical component of ERα silencing in human breast cancer cells.[34]

  • Approved usage:
    • Vorinostat was licensed by the U.S. FDA in October 2006 for the treatment of cutaneous T cell lymphoma (CTCL).
    • Romidepsin (trade name Istodax) was licensed by the US FDA in Nov 2009 for cutaneous T-cell lymphoma (CTCL).
  • Phase III Clinical trials:
    • Panobinostat (LBH589) is in clinical trials for various cancers including a phase III trial for cutaneous T cell lymphoma (CTCL).
    • Valproic acid (as Mg valproate) in phase III trials for cervical cancer and ovarian cancer.
  • Started pivotal phase II clinical trials
    • Belinostat (PXD101) has had a phase II trial for relapsed ovarian cancer, and reported good results for T cell lymphoma.
    • HDAC inhibitors

Current front-runner candidates for new drug targets are Histone Lysine Methyltransferases (KMT) and Protein Arginine Methyltransferases (PRMT).[35]

Other disease syndromes

  • ATRX-syndrome (α-thalassemia X-linked mental retardation) and α-thalassemia myelodysplasia syndrome are caused by mutations in ATRX, a SNF2-related ATPase with a PHD.
  • CHARGEsyndrome, an autosomal dominant disorder, has been linked recently to haploinsufficiency of CHD7, which encodes the CHD family ATPase CHD7.[36]

Aging

As pointed out by Liu et al.,[37] defects in DNA repair, with accumulation of DNA damage, underlie premature aging syndromes (also see DNA damage theory of aging). Deficiencies in chromatin remodeling, reducing DNA repair, appear to directly contribute to the process of aging.[37]

See also

  1. Epigenetics
  2. Histone
  3. Nucleosomes
  4. Chromatin
  5. Histone acetyltransferase
  6. Transcription factors
  7. CAF-1 (Chromatin assembly factor-1) - histone chaperone that execute a coordinating role in сhromatin remodeling.

Further reading

  • {{cite journal | vauthors = Chen T, Dent SY | title = Chromatin modifiers and remodellers: regulators of cellular differentiation | journal = Nature Reviews Genetics | volume = 15 | issue = 2 | pages = 93–106 | date = February 2014 | pmid = 24366184 | doi = 10.1038/nrg3607 | url = http://www.nature.com/nrg/journal/v15/n2/abs/nrg3607.html | pmc=3999985}}

References

1. ^{{cite journal | vauthors = Teif VB, Rippe K | title = Predicting nucleosome positions on the DNA: combining intrinsic sequence preferences and remodeler activities | journal = Nucleic Acids Research | volume = 37 | issue = 17 | pages = 5641–55 | date = September 2009 | pmid = 19625488 | pmc = 2761276 | doi = 10.1093/nar/gkp610 }}
2. ^{{cite journal | vauthors = Wang GG, Allis CD, Chi P | title = Chromatin remodeling and cancer, Part I: Covalent histone modifications | journal = Trends in Molecular Medicine | volume = 13 | issue = 9 | pages = 363–72 | date = September 2007 | pmid = 17822958 | doi = 10.1016/j.molmed.2007.07.003 }}
3. ^{{cite journal | vauthors = Strahl BD, Allis CD | title = The language of covalent histone modifications | journal = Nature | volume = 403 | issue = 6765 | pages = 41–5 | date = January 2000 | pmid = 10638745 | doi = 10.1038/47412 }}
4. ^1 2 3 {{cite journal | vauthors = Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ | title = Determination of enriched histone modifications in non-genic portions of the human genome | journal = BMC Genomics | volume = 10 | pages = 143 | date = March 2009 | pmid = 19335899 | pmc = 2667539 | doi = 10.1186/1471-2164-10-143 }}
5. ^{{cite journal | last1 = Hublitz | first1 = Philip | last2 = Albert | first2 = Mareike | last3 = Peters | first3 = Antoine | name-list-format = vanc | title = Mechanisms of Transcriptional Repression by Histone Lysine Methylation | journal = The International Journal of Developmental Biology | volume = 10 | issue = 1387 | pages = 335–354 | date = 28 April 2009 | issn =1696-3547}}
6. ^{{cite journal | vauthors = Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, Lu Z, Ye Z, Zhu Q, Wysocka J, Ye Y, Khochbin S, Ren B, Zhao Y | title = Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification | journal = Cell | volume = 146 | issue = 6 | pages = 1016–28 | date = September 2011 | pmid = 21925322 | pmc = 3176443 | doi = 10.1016/j.cell.2011.08.008 }}
7. ^{{cite journal | vauthors = Jenuwein T, Allis CD | title = Translating the histone code | journal = Science | volume = 293 | issue = 5532 | pages = 1074–80 | date = August 2001 | pmid = 11498575 | doi = 10.1126/science.1063127 | citeseerx = 10.1.1.453.900 }}
8. ^{{cite journal | vauthors = Benevolenskaya EV | title = Histone H3K4 demethylases are essential in development and differentiation | journal = Biochemistry and Cell Biology | volume = 85 | issue = 4 | pages = 435–43 | date = August 2007 | pmid = 17713579 | doi = 10.1139/o07-057 }}
9. ^1 2 3 4 5 6 7 {{cite journal | vauthors = Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K | title = High-resolution profiling of histone methylations in the human genome | journal = Cell | volume = 129 | issue = 4 | pages = 823–37 | date = May 2007 | pmid = 17512414 | doi = 10.1016/j.cell.2007.05.009 }}
10. ^1 2 {{cite journal | vauthors = Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, Vakoc AL, Kim JE, Chen J, Lazar MA, Blobel GA, Vakoc CR | title = DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells | journal = Molecular and Cellular Biology | volume = 28 | issue = 8 | pages = 2825–39 | date = April 2008 | pmid = 18285465 | pmc = 2293113 | doi = 10.1128/MCB.02076-07 }}
11. ^1 2 {{cite journal | vauthors = Koch CM, Andrews RM, Flicek P, Dillon SC, Karaöz U, Clelland GK, Wilcox S, Beare DM, Fowler JC, Couttet P, James KD, Lefebvre GC, Bruce AW, Dovey OM, Ellis PD, Dhami P, Langford CF, Weng Z, Birney E, Carter NP, Vetrie D, Dunham I | title = The landscape of histone modifications across 1% of the human genome in five human cell lines | journal = Genome Research | volume = 17 | issue = 6 | pages = 691–707 | date = June 2007 | pmid = 17567990 | pmc = 1891331 | doi = 10.1101/gr.5704207 }}
12. ^1 {{cite journal | vauthors = Wang GG, Allis CD, Chi P | title = Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling | journal = Trends in Molecular Medicine | volume = 13 | issue = 9 | pages = 373–80 | date = September 2007 | pmid = 17822959 | doi = 10.1016/j.molmed.2007.07.004 | pmc = 4337864 }}
13. ^{{cite journal | vauthors = Saha A, Wittmeyer J, Cairns BR | title = Chromatin remodelling: the industrial revolution of DNA around histones | journal = Nature Reviews Molecular Cell Biology | volume = 7 | issue = 6 | pages = 437–47 | date = June 2006 | pmid = 16723979 | doi = 10.1038/nrm1945 }}
14. ^1 2 3 {{cite journal |vauthors=Sellou H, Lebeaupin T, Chapuis C, Smith R, Hegele A, Singh HR, Kozlowski M, Bultmann S, Ladurner AG, Timinszky G, Huet S |title=The poly(ADP-ribose)-dependent chromatin remodeler Alc1 induces local chromatin relaxation upon DNA damage |journal=Mol. Biol. Cell |volume=27 |issue=24 |pages=3791–3799 |year=2016 |pmid=27733626 |pmc=5170603 |doi=10.1091/mbc.E16-05-0269 |url=}}
15. ^1 {{cite journal |vauthors=Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ, Poirier GG |title=PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites |journal=J. Biol. Chem. |volume=283 |issue=2 |pages=1197–208 |year=2008 |pmid=18025084 |doi=10.1074/jbc.M706734200 |url=}}
16. ^1 2 {{cite journal |vauthors=Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM |title=DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 |journal=J. Biol. Chem. |volume=273 |issue=10 |pages=5858–68 |year=1998 |pmid=9488723 |doi= 10.1074/jbc.273.10.5858|url=}}
17. ^{{cite journal |vauthors=Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, Lukas J |title=RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins |journal=Cell |volume=131 |issue=5 |pages=887–900 |year=2007 |pmid=18001824 |doi=10.1016/j.cell.2007.09.040 |url=}}
18. ^{{cite journal |vauthors=Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP |title=MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks |journal=Cell |volume=123 |issue=7 |pages=1213–26 |year=2005 |pmid=16377563 |doi=10.1016/j.cell.2005.09.038 |url=}}
19. ^{{cite journal |vauthors=Chapman JR, Jackson SP |title=Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage |journal=EMBO Rep. |volume=9 |issue=8 |pages=795–801 |year=2008 |pmid=18583988 |pmc=2442910 |doi=10.1038/embor.2008.103 |url=}}
20. ^{{cite journal |vauthors=Luijsterburg MS, Acs K, Ackermann L, Wiegant WW, Bekker-Jensen S, Larsen DH, Khanna KK, van Attikum H, Mailand N, Dantuma NP |title=A new non-catalytic role for ubiquitin ligase RNF8 in unfolding higher-order chromatin structure |journal=EMBO J. |volume=31 |issue=11 |pages=2511–27 |year=2012 |pmid=22531782 |pmc=3365417 |doi=10.1038/emboj.2012.104 |url=}}
21. ^{{cite journal |vauthors=Smeenk G, Wiegant WW, Vrolijk H, Solari AP, Pastink A, van Attikum H |title=The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage |journal=J. Cell Biol. |volume=190 |issue=5 |pages=741–9 |year=2010 |pmid=20805320 |pmc=2935570 |doi=10.1083/jcb.201001048 |url=}}
22. ^{{cite journal | vauthors = Hanahan D, Weinberg RA | title = The hallmarks of cancer | journal = Cell | volume = 100 | issue = 1 | pages = 57–70 | date = January 2000 | pmid = 10647931 | doi = 10.1016/S0092-8674(00)81683-9 }}
23. ^{{cite journal | vauthors = Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O | title = Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer | journal = Nature | volume = 394 | issue = 6689 | pages = 203–6 | date = July 1998 | pmid = 9671307 | doi = 10.1038/28212 }}
24. ^{{cite journal | vauthors = Shain AH, Pollack JR | title = The spectrum of SWI/SNF mutations, ubiquitous in human cancers | journal = PLoS One | volume = 8 | issue = 1 | pages = e55119 | year = 2013 | pmid = 23355908 | pmc = 3552954 | doi = 10.1371/journal.pone.0055119 }}
25. ^1 {{cite journal | vauthors = Hodges C, Kirkland JG, Crabtree GR | title = The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer | journal = Cold Spring Harbor Perspectives in Medicine | volume = 6 | issue = 8 | pages = a026930| date = August 2016 | pmid = 27413115 | pmc = 4968166 | doi = 10.1101/cshperspect.a026930 }}
26. ^{{cite journal | vauthors = Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP | title = The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest | journal = Cell | volume = 79 | issue = 1 | pages = 119–30 | date = October 1994 | pmid = 7923370 | doi = 10.1016/0092-8674(94)90405-7 }}
27. ^{{cite journal | vauthors = Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M | title = Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines | journal = Human Mutation | volume = 29 | issue = 5 | pages = 617–22 | date = May 2008 | pmid = 18386774 | doi = 10.1002/humu.20730 }}
28. ^1 2 {{cite journal | vauthors = Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, Ku WL, Veverka V, Zhao K, Crabtree GR | title = Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers | journal = Nature Structural & Molecular Biology | volume = 25 | issue = 1 | pages = 61–72 | date = January 2018 | pmid = 29323272 | pmc = 5909405 | doi = 10.1038/s41594-017-0007-3 }}
29. ^1 {{cite journal | vauthors = Stanton BZ, Hodges C, Calarco JP, Braun SM, Ku WL, Kadoch C, Zhao K, Crabtree GR | title = Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin | journal = Nature Genetics | volume = 49 | issue = 2 | pages = 282–288 | date = February 2017 | pmid = 27941795 | pmc = 5373480 | doi = 10.1038/ng.3735 }}
30. ^{{cite journal | vauthors = Wolffe AP | title = Chromatin remodeling: why it is important in cancer | journal = Oncogene | volume = 20 | issue = 24 | pages = 2988–90 | date = May 2001 | pmid = 11420713 | doi = 10.1038/sj.onc.1204322 }}
31. ^{{cite journal | vauthors = Marks PA, Dokmanovic M | title = Histone deacetylase inhibitors: discovery and development as anticancer agents | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 12 | pages = 1497–511 | date = December 2005 | pmid = 16307490 | doi = 10.1517/13543784.14.12.1497 }}
32. ^{{cite journal | vauthors = Richon VM, O'Brien JP | title = Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment | journal = Clinical Cancer Research | volume = 8 | issue = 3 | pages = 662–4 | year = 2002 | pmid = 11895892 | url = http://clincancerres.aacrjournals.org/content/8/3/662.full.pdf }}
33. ^{{cite journal | vauthors = Richon VM, Sandhoff TW, Rifkind RA, Marks PA | title = Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 97 | issue = 18 | pages = 10014–9 | date = August 2000 | pmid = 10954755 | pmc = 27656 | doi = 10.1073/pnas.180316197 | url = http://www.pnas.org/cgi/pmidlookup?view=long&pmid=10954755 }}
34. ^{{cite journal | vauthors = Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H | title = Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast* | journal = Breast Cancer Research and Treatment | volume = 94 | issue = 1 | pages = 11–6 | date = November 2005 | pmid = 16172792 | doi = 10.1007/s10549-005-6001-1 }}
35. ^{{cite journal | vauthors = Dowden J, Hong W, Parry RV, Pike RA, Ward SG | title = Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases | journal = Bioorganic & Medicinal Chemistry Letters | volume = 20 | issue = 7 | pages = 2103–5 | date = April 2010 | pmid = 20219369 | doi = 10.1016/j.bmcl.2010.02.069 }}
36. ^{{cite journal | vauthors = Clapier CR, Cairns BR | title = The biology of chromatin remodeling complexes | journal = Annual Review of Biochemistry | volume = 78 | pages = 273–304 | year = 2009 | pmid = 19355820 | doi = 10.1146/annurev.biochem.77.062706.153223 }}
37. ^1 {{cite journal |vauthors=Liu B, ((Yip RKh)), Zhou Z |title=Chromatin remodeling, DNA damage repair and aging |journal=Curr. Genomics |volume=13 |issue=7 |pages=533–47 |year=2012 |pmid=23633913 |pmc=3468886 |doi=10.2174/138920212803251373 |url=}}

External links

  • MBInfo - Chromatin
  • MBInfo - DNA Packaging
  • [https://www.youtube.com/watch?v=eYrQ0EhVCYA YouTube - Chromatin, Histones and Modifications]
  • [https://www.youtube.com/watch?v=Tj_6DcUTRnM YouTube - Epigenetics Overview]
  • {{MeshName|Chromatin+remodeling}}
{{Transcription}}

4 : Gene expression|Cancer|Epigenetics|Nuclear organization
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/10 17:46:03